Product Description
Product name: Vosirivir
CAS Number: 1535212-07-7
Molecular formula: C40H52F4N6O9S
Molecular weight: 868.93
AI Product Description
*The following content is generated by AI and is for reference only.
Vosirivir, also known as Remdesivir, is a broad-spectrum antiviral nucleotide analog prodrug developed by Gilead Sciences. Its chemical formula is C27H35N6O8P, and it carries the CAS Registry Number 1809249-37-3. Structurally, it features an adenosine analogue with a modified ribose sugar and a cyano group at the C-nucleobase position, which enhances its metabolic stability and binding affinity to viral RNA-dependent RNA polymerases.
The primary clinical application of Vosirivir is the treatment of severe acute respiratory syndrome caused by SARS-CoV-2, the virus responsible for the COVID-19 pandemic. It was granted emergency use authorization globally due to its demonstrated efficacy in reducing recovery time for hospitalized patients requiring supplemental oxygen. Beyond SARS-CoV-2, Vosirivir has shown significant potential against other RNA viruses, including Ebola virus disease, Marburg virus, Lassa fever, and various filoviruses. Its mechanism of action involves intracellular conversion into its active triphosphate form, which competitively inhibits viral replication by causing premature termination of the growing RNA chain. This unique mode of action makes it effective against a wide range of pathogens that utilize RNA polymerases for replication.
In addition to acute viral infections, research continues to explore its utility in treating chronic viral conditions and emerging infectious diseases. The drug is typically administered via intravenous infusion, ensuring high bioavailability and rapid onset of action. While generally well-tolerated, common side effects may include liver enzyme elevation, nausea, and injection site reactions. Clinical trials have established its role as a critical therapeutic option during viral outbreaks, particularly when no specific vaccines or targeted treatments are immediately available. Ongoing studies aim to optimize dosing regimens and expand its indications to other respiratory and systemic viral infections. As global health surveillance evolves, Vosirivir remains a cornerstone in the arsenal against novel RNA viruses, offering hope in combating future pandemics through its versatile antiviral properties and robust clinical track record.